Abstract
This article describes recent advances in the diagnostic and therapeutic management of small cell lung cancer, particularly, the development of immune checkpoint inhibitors and new agents targeting DLL3. He also cites still debatable issues such as pre-therapeutic explorations, thoracic radiotherapy, and prophylactic cerebral irradiation. Finally, therapeutic approaches targeting DNA damage repair abnormalities are discussed.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
